Market Overview

Barclays Initiates Protagonist At Overweight, Sees Upside Value In Proprietary Peptide Platform

Share:
Barclays Initiates Protagonist At Overweight, Sees Upside Value In Proprietary Peptide Platform
Related
33 Stocks Moving In Thursday's Mid-Day Session
30 Stocks Moving In Thursday's Pre-Market Session

Protagonist Therapeutics Inc’s (NASDAQ: PTGX) lead asset PTG-100 in IBD has “significant end-market opportunity” and there is “upside value” in the company’s proprietary peptide platform, validated by four development-stage assets to date, Barclays’ Douglas D. Tsao said in a report. He initiated coverage of the company with an Overweight rating and a price target of $18.

Lead Candidate

Analyst Tsao estimated over $1.1 billion in revenues for PTG-100 in ulcerative colitis. He added that there was potential for expanded use into Crohn’s disease and pediatric IBD. Protagonist is on track to submitting its IND for PTG-100 in Q3 this year and intends to commence the Phase 2b trial in Q4, the readout of which is expected in the first half of 2018.

Related Link: Merk Remains Stable Following Discontinuation Of Odanacatib Development Program

Peptide Platform

Protagonist’s platform has produced additional development-stage assets, Tsao noted. PTG-200 is being developed as an oral treatment for CD targeting the IL-23 receptor, “unlike other drugs focused on that target ligand.” The development took six to nine fewer months than PTG-100 based on platform learnings.

“We see potential for fixed-dose therapy with PTG-100, but estimate $660M in revenues for PTG-200 in CD alone. PTG-300 is a novel mimetic hepcidin peptide intended to treat orphan iron-overload disorders which occur in up to ~0.5% of adults,” the analyst wrote. He added that Protagonist’s platform was protected by IP till 2034.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for PTGX

DateFirmActionFromTo
Nov 2017BMO CapitalMaintainsOutperform
Oct 2017BMO CapitalMaintainsOutperform
Jul 2017BTIG ResearchInitiates Coverage OnBuy

View More Analyst Ratings for PTGX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

 

Related Articles (PTGX)

View Comments and Join the Discussion!

Partner Center